Sign Up
Stories
BioPharma Shift: Coherus-Sandoz Acquisition
Share
Advancements in Cancer Treatment and Mar...
Biopharma and Healthcare Innovations Upd...
Biopharmaceutical Companies Merge and Pr...
4P-Pharma Secures €15 Million Funding
AB Science's Medical Breakthrough Webcas...
ABBio Innovates Antibody Development
Overview
API
Coherus BioSciences divests CIMERLI ophthalmology franchise to Sandoz for $170 million, focusing on oncology. Sandoz acquires CIMERLI to bolster its US ophthalmic business, expanding treatment options for retinal diseases.
Ask a question
How could this strategic acquisition influence the future landscape of biosimilars and generics in the healthcare industry?
How might Coherus' increased focus on oncology impact its competitive positioning in the pharmaceutical market?
What potential innovations or developments could arise from Sandoz's acquisition of CIMERLI in the ophthalmic sector?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage